Medications

Semaglutide: Complete Guide to Dosing, Results & Side Effects

GLP-1 Companion · 10 min read

Semaglutide has become one of the most widely recognized medications in the world, powering brand names like Ozempic, Wegovy, and Rybelsus. Originally developed by Novo Nordisk for type 2 diabetes, it rapidly gained attention for its significant weight-loss effects and has reshaped how clinicians approach both conditions.

What Is Semaglutide?

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the natural incretin hormone GLP-1, which is released after eating to stimulate insulin, suppress glucagon, slow gastric emptying, and signal satiety to the brain. Semaglutide has been structurally modified to resist degradation by the enzyme DPP-4, giving it a half-life of approximately one week—which is why it can be dosed once weekly.

All Brand Names at a Glance

• Ozempic: Injectable semaglutide approved for type 2 diabetes (doses up to 2 mg weekly).
• Wegovy: Injectable semaglutide approved for chronic weight management (doses up to 2.4 mg weekly).
• Rybelsus: Oral semaglutide tablet approved for type 2 diabetes (daily doses of 3 mg, 7 mg, or 14 mg).

Dosing Schedules by Brand

Ozempic (Injectable, for Type 2 Diabetes)

1. Weeks 1–4: 0.25 mg once weekly (initiation dose)
2. Weeks 5–8: 0.5 mg once weekly
3. If needed, increase to 1 mg once weekly after at least 4 weeks
4. Maximum dose: 2 mg once weekly (for additional glycemic control)

Wegovy (Injectable, for Weight Management)

1. Weeks 1–4: 0.25 mg once weekly
2. Weeks 5–8: 0.5 mg once weekly
3. Weeks 9–12: 1 mg once weekly
4. Weeks 13–16: 1.7 mg once weekly
5. Week 17 onward: 2.4 mg once weekly (maintenance dose)

Rybelsus (Oral Tablet, for Type 2 Diabetes)

1. First 30 days: 3 mg once daily (initiation)
2. Day 31 onward: 7 mg once daily
3. If additional control is needed: 14 mg once daily
4. Must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before eating or drinking anything else

Weight Loss Results from Clinical Trials

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program provided robust evidence for semaglutide's weight-loss efficacy at the 2.4 mg weekly dose.

• STEP 1: Adults without diabetes lost an average of 14.9% of body weight (approximately 33 lbs) over 68 weeks on semaglutide 2.4 mg, compared to 2.4% on placebo.
• STEP 2: Adults with type 2 diabetes lost an average of 9.6% of body weight on semaglutide 2.4 mg.
• STEP 3: Combined with intensive behavioral therapy, participants lost an average of 16% of body weight.
• STEP 5: Over 2 years of treatment, participants maintained an average weight loss of 15.2%.
• SELECT trial: Demonstrated a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease.

The SELECT trial was a landmark moment: it proved that semaglutide does not just help people lose weight—it also reduces the risk of heart attacks and strokes.

Side Effects and What to Expect

Gastrointestinal side effects are the most common and typically follow a predictable timeline. Understanding this pattern can help you manage expectations and stay on track.

Side Effects Timeline

• Weeks 1–4 (0.25 mg): Most patients experience mild nausea and reduced appetite. Some report no side effects at this low starting dose.
• Weeks 5–8 (0.5 mg): Nausea may intensify after the first dose increase. Constipation or diarrhea can emerge.
• Weeks 9–16 (1 mg–1.7 mg): GI symptoms often peak during these escalation steps. Fatigue and headaches are also reported.
• Week 17+ (2.4 mg maintenance): Side effects typically stabilize and improve. Most patients report that nausea becomes infrequent or resolves entirely after 8–12 weeks at a stable dose.

Less Common but Important Side Effects

• Pancreatitis (rare but serious—seek emergency care for severe abdominal pain radiating to the back)
• Gallbladder disease, including gallstones
• Hypoglycemia, especially if combined with insulin or sulfonylureas
• Injection site reactions
• Increased heart rate (typically small, 2–4 bpm)
• Thyroid C-cell tumors (boxed warning based on rodent studies; human risk unclear)

Compounded Semaglutide: What You Should Know

Due to supply shortages and high costs, compounded versions of semaglutide have become available through compounding pharmacies. These are custom-prepared formulations and are not FDA-approved products. The FDA has issued warnings about potential safety concerns with compounded semaglutide, including inconsistent dosing, contamination risks, and the use of salt forms (such as semaglutide sodium) that have not been studied in clinical trials.

Tips for Managing Side Effects

• Eat slowly and stop when you feel satisfied—not full.
• Choose bland, low-fat foods during dose escalation periods.
• Stay hydrated with water, herbal tea, or electrolyte drinks.
• Consider ginger tea or ginger chews for nausea.
• Avoid lying down immediately after eating.
• If constipation occurs, increase fiber intake gradually and consider a stool softener.
• Track symptoms daily to identify patterns and share them with your provider.

The Bottom Line

Semaglutide is a well-studied, effective GLP-1 receptor agonist with strong evidence for both blood sugar control and weight loss. Whether you are using Ozempic, Wegovy, or Rybelsus, the key to success is proper dose escalation, realistic expectations about the side-effect timeline, and a commitment to lifestyle changes that complement the medication. Talk to your healthcare provider to determine which brand and dose are right for your individual needs.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Ozempic (semaglutide) Prescribing Information. Novo Nordisk.